{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:04:12Z","timestamp":1788811452985,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children. Differences are found among ethnic groups in the results of the treatment of pediatric ALL. In general, children with a high level of native American ancestry tend to respond less positively to ALL treatments, which may be related to specific genomic variants found in native American groups. Despite the evidence, few data are available on the distribution of the pharmacogenomic variants relevant to the treatment of ALL in traditional Amerindian populations, such the those of the Amazon region. Given this, the present study investigated 27 molecular markers related to the treatment of ALL in Amerindians from Brazilian Amazonia and compared the frequencies with those recorded previously on five continents, that are available in the 1,000 Genomes database. The variation in the genotype frequencies among populations was evaluated using Fisher\u2019s exact test. The False Discovery Rate method was used to correct the results of the multiple analyses. Significant differences were found in the frequencies of the majority of markers between the Amerindian populations and those of other regions around the world. These findings highlight the unique genetic profile of the indigenous population of Brazilian Amazonia, which may reflect a distinct therapeutic profile for the treatment of ALL in these populations.<\/jats:p>","DOI":"10.1038\/s41598-020-67312-y","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T10:02:52Z","timestamp":1592992972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in Amazonian native Americans population"],"prefix":"10.1038","volume":"10","author":[{"given":"Darlen Cardoso","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alayde Vieira","family":"Wanderley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Mauricio Ribeiro","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano Cordeiro","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Borges Andrade","family":"de S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Rodrigues","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Andr\u00e9 Conde","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiane Piedade","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cohen-Paes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Pereira Colares","family":"Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Carla Gomes","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur Luiz da Costa","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Farias","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Salim","family":"Khayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Pimentel","family":"de Assump\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ney Pereira Carneiro","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"67312_CR1","first-page":"551","volume":"29","author":"CH Pui","year":"2011","unstructured":"Pui, C. H., Carroll, W. L., Meshinchi, S. & Arceci, R. J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551\u2013565 (2011).","journal-title":"J. Clin. Oncol."},{"key":"67312_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescente cancer statistics. CA Cancer J. Clin. 64, 83\u2013103 (2014).","journal-title":"CA Cancer J. Clin."},{"key":"67312_CR3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/PGS.15.62","volume":"16","author":"MS Hareedy","year":"2015","unstructured":"Hareedy, M. S. et al. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics 16, 1119\u20131134 (2015).","journal-title":"Pharmacogenomics"},{"key":"67312_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","volume":"23","author":"E Lopez-Lopez","year":"2013","unstructured":"Lopez-Lopez, E. et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genom. 23, 53\u201361 (2013).","journal-title":"Pharmacogenet Genom."},{"key":"67312_CR5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2000.18.4.813","volume":"18","author":"BH Pollock","year":"2000","unstructured":"Pollock, B. H. et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J. Clin. Oncol. 18, 813\u2013823 (2000).","journal-title":"J. Clin. Oncol."},{"key":"67312_CR6","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2002-02-0395","volume":"100","author":"S Bhatia","year":"2000","unstructured":"Bhatia, S. et al. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 100, 1957\u20131964 (2000).","journal-title":"Blood"},{"key":"67312_CR7","first-page":"2690","volume":"104","author":"CH Pui","year":"2004","unstructured":"Pui, C. H. et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children\u2019s Research Hospital. Blood 104, 2690\u20132696 (2004).","journal-title":"Blood"},{"key":"67312_CR8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.290.15.2008","volume":"290","author":"NS Kadan-Lottick","year":"2003","unstructured":"Kadan-Lottick, N. S., Ness, K. K., Bhatia, S. & Gurney, J. G. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 290, 2008\u20132014 (2003).","journal-title":"JAMA"},{"key":"67312_CR9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ng.763","volume":"43","author":"JJ Yang","year":"2011","unstructured":"Yang, J. J. et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43, 237\u2013241 (2011).","journal-title":"Nat. Genet."},{"key":"67312_CR10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2018.09.003","volume":"74","author":"DC de Carvalho","year":"2018","unstructured":"de Carvalho, D. C. et al. Pharmacogenomics and variations in the risk of toxicity during the consolidation\/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon. Leuk. Res. 74, 10\u201313 (2018).","journal-title":"Leuk. Res."},{"key":"67312_CR11","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1038\/s41598-019-43610-y","volume":"9","author":"JCG Rodrigues","year":"2019","unstructured":"Rodrigues, J. C. G. et al. Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians. Sci. Rep. 9, 7201 (2019).","journal-title":"Sci. Rep."},{"key":"67312_CR12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/humu.21159","volume":"31","author":"NP Santos","year":"2010","unstructured":"Santos, N. P. et al. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum. Mutat. 31, 184\u2013190 (2010).","journal-title":"Hum. Mutat."},{"key":"67312_CR13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10709-016-9894-1","volume":"44","author":"BR Ramos","year":"2016","unstructured":"Ramos, B. R. et al. Neither self-reported ethnicity nor declared family origin are reliable indicators of genomic ancestry. Genetica 44, 259\u2013265 (2016).","journal-title":"Genetica"},{"key":"67312_CR14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. B"},{"key":"67312_CR15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ng.585","volume":"42","author":"AL Sherborne","year":"2010","unstructured":"Sherborne, A. L. et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat. Genet. 42, 492\u2013494 (2010).","journal-title":"Nat. Genet."},{"key":"67312_CR16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3109\/10428194.2010.511356","volume":"51","author":"J Vijayakrishnan","year":"2010","unstructured":"Vijayakrishnan, J. et al. Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence. Leuk. Lymphoma 51, 1870\u20131874 (2010).","journal-title":"Leuk. Lymphoma"},{"key":"67312_CR17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/leu.2013.130","volume":"27","author":"KM Walsh","year":"2013","unstructured":"Walsh, K. M. et al. Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children. Leukemia 27, 2416\u20132419 (2013).","journal-title":"Leukemia"},{"key":"67312_CR18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gde.2016.06.016","volume":"41","author":"P Skoglund","year":"2016","unstructured":"Skoglund, P. & Reich, D. A genomic view of the peopling of the Americas. Curr Opin Genet Dev. 41, 27\u201335 (2016).","journal-title":"Curr Opin Genet Dev."},{"key":"67312_CR19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/evan.21478","volume":"25","author":"JF Hoffecker","year":"2016","unstructured":"Hoffecker, J. F., Elias, S. A., O\u2019Rourke, D. H., Scott, G. R. & Bigelow, N. H. Beringia and the global dispersal of modern humans. Evol. Anthropol. 25, 64\u201378 (2016).","journal-title":"Evol. Anthropol."},{"key":"67312_CR20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/clpt.2014.92","volume":"96","author":"BC Carleton","year":"2014","unstructured":"Carleton, B. C. et al. Genetic markers of cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 96, 296\u2013298 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"67312_CR21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/pbc.26189","volume":"64","author":"NK Zgheib","year":"2017","unstructured":"Zgheib, N. K. et al. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leucemia at the Children\u2019s Cancer Center of Lebanon. Pediatr. Blood Cancer 64, 146\u2013150 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"67312_CR22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12885-018-4398-2","volume":"18","author":"H Zhou","year":"2018","unstructured":"Zhou, H. et al. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer 18, 516 (2018).","journal-title":"BMC Cancer"},{"key":"67312_CR23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.critrevonc.2012.04.003","volume":"84","author":"JM Vagace","year":"2012","unstructured":"Vagace, J. M., de la Maya, M. D., Caceres-Marzal, C., Gonzalez de Murillo, S. & Gervasini, G. Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia\/lymphoma. Crit. Rev. Oncol. Hematol. 84, 274\u2013286 (2012).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"67312_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FPC.0000000000000069","volume":"24","author":"NK Zgheib","year":"2014","unstructured":"Zgheib, N. K. et al. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genom. 24, 387\u2013396 (2014).","journal-title":"Pharmacogenet Genom."},{"key":"67312_CR25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14622416.5.7.819","volume":"5","author":"M Krajinovic","year":"2004","unstructured":"Krajinovic, M. & Moghrabi, A. Pharmacogenetics of methotrexate. Pharmacogenomics 5, 819\u2013834 (2004).","journal-title":"Pharmacogenomics"},{"key":"67312_CR26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3109\/10428194.2011.639880","volume":"53","author":"N Er\u010dulj","year":"2012","unstructured":"Er\u010dulj, N., Kotnik, B. F., Debeljak, M., Jazbec, J. & Dol\u017ean, V. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk. Lymphoma 53, 1096\u20131104 (2012).","journal-title":"Leuk. Lymphoma"},{"key":"67312_CR27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2004-12-4941","volume":"106","author":"R Jonge","year":"2005","unstructured":"Jonge, R. et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106, 717\u2013720 (2005).","journal-title":"Blood"},{"key":"67312_CR28","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/leu.2008.66","volume":"22","author":"L Huang","year":"2008","unstructured":"Huang, L., Tissing, W. J., de Jonge, R., van Zelst, B. D. & Pieters, R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 22, 1798\u20131800 (2008).","journal-title":"Leukemia"},{"key":"67312_CR29","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","volume":"27","author":"LR Trevi\u00f1o","year":"2009","unstructured":"Trevi\u00f1o, L. R. et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27, 5972\u20135978 (2009).","journal-title":"J. Clin. Oncol."},{"key":"67312_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","volume":"22","author":"LB Ramsey","year":"2012","unstructured":"Ramsey, L. B. et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22, 1\u20138 (2012).","journal-title":"Genome Res."},{"key":"67312_CR31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","volume":"121","author":"LB Ramsey","year":"2013","unstructured":"Ramsey, L. B. et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121, 898\u2013904 (2013).","journal-title":"Blood"},{"key":"67312_CR32","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","volume":"121","author":"S Radtke","year":"2013","unstructured":"Radtke, S. et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121, 5145\u20135153 (2013).","journal-title":"Blood"},{"key":"67312_CR33","first-page":"562","volume":"35","author":"HM James","year":"2008","unstructured":"James, H. M. et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J. Rheumatol. 35, 562\u2013571 (2008).","journal-title":"J. Rheumatol."},{"key":"67312_CR34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2133.2008.08898.x","volume":"160","author":"RB Warren","year":"2009","unstructured":"Warren, R. B. et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br. J. Dermatol. 160, 438\u2013441 (2009).","journal-title":"Br. J. Dermatol."},{"key":"67312_CR35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/tpj.2012.7","volume":"13","author":"SA Owen","year":"2013","unstructured":"Owen, S. A. et al. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenom. J. 13, 227\u2013234 (2013).","journal-title":"Pharmacogenom. J."},{"key":"67312_CR36","first-page":"1113","volume":"91","author":"I Costea","year":"2006","unstructured":"Costea, I., Moghrabi, A., Laverdiere, C., Graziani, A. & Krajinovic, M. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 91, 1113\u20131116 (2006).","journal-title":"Haematologica"},{"key":"67312_CR37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00228-012-1341-3","volume":"69","author":"B Jekic","year":"2013","unstructured":"Jekic, B. et al. Association of the TYMS 3G\/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur. J. Clin. Pharmacol. 69, 377\u2013383 (2013).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"67312_CR38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2125.2010.03814.x","volume":"71","author":"M Yanagimachi","year":"2011","unstructured":"Yanagimachi, M. et al. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J. Clin. Pharmacol. 71, 237\u2013243 (2011).","journal-title":"Br J. Clin. Pharmacol."},{"key":"67312_CR39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00280-014-2507-8","volume":"74","author":"SM Wang","year":"2014","unstructured":"Wang, S. M., Sun, L. L., Zeng, W. X., Wu, W. S. & Zhang, G. L. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 74, 283\u2013289 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"67312_CR40","first-page":"100188","volume":"27","author":"DC Carvalho","year":"2019","unstructured":"Carvalho, D. C. et al. Association of genes ARID5B, CEBPE and folate pathway with acute lymphoblastic leukemia in a population from the Brazilian Amazon region. Leuk. Res. Rep. 27, 100188 (2019).","journal-title":"Leuk. Res. Rep."},{"key":"67312_CR41","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3109\/10428194.2013.867492","volume":"55","author":"DH Fang","year":"2014","unstructured":"Fang, D. H., Ji, Q., Fan, C. H., An. Q. & Li, J. Methionine synthase reductase A66G polymorphism and leukemia risk: evidence from published studies. Leuk. Lymphoma 55, 1910\u20131914 (2014).","journal-title":"Leuk. Lymphoma"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67312-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T08:55:45Z","timestamp":1723107345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67312-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67312"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67312-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10292"}}